Observing Gene Changes in Restless Legs Syndrome Patients on Dopamine Agonists
This observational study is looking at how long-term treatment with dopamine agonist medications like Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (Neupro), Apomorphine (Apokyn), and Bromocriptine (Parlodel) affects certain genes in people with Restless Legs Syndrome (RLS). Researchers will collect a nasal swab from participants to check for changes in these genes. The study aims to understand if the duration of dopamine agonist use leads to differences in gene expression. You may be able to join if you are between 18 and 60 years old, have RLS, and are currently taking a dopamine agonist. The study is currently unclear on its recruitment status and plans to enroll 50 participants.
- Study design
- This is an observational study involving 50 participants. It compares gene expression in two groups: those on dopamine agonists for less than one month, and those on them for six months or more.
- What's involved
- The study involves collecting nasal swabs from participants. The primary endpoint is measured at 1 week.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 1 week, indicating a short follow-up period for this specific measurement.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment
At a glance
Conditions
NCT06726785
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Alethios Inc
San Francisco, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- To analyze the effect of duration of dopamine agonist treatments for changes in dopaminergic genes expression using nasal epithelial cells.1 week
Gene expression will be measured and reported as the Fold change, which is the ratio of expression levels between the DRD2 experimental gene vs GAPDH housekeeping gene expression and reported as the Fold change which will indicate the magnitude of upregulation or downregulation of the DRD2 gene. A fold change \>= 2 will be used as the minimum baseline to indicate upregulation and a fold change \< = 1/2 will be used as the minimum baseline to indicate downregulation.